A US-funded clinical trial designed to test whether withholding the hepatitis B birth-dose vaccine from newborns in Guinea-Bissau would improve overall mortality has been shut down. Danish lead researcher Frederik Schaltz-Buchholzer confirmed the study "will not move forward" after the Guinea-Bissau government denied approval and searched the offices of the Bandim Health Project, seizing the vaccine supply. The trial's design was the problem. Danish researchers hypothesized that giving hepatitis B vaccine alongside the BCG tuberculosis vaccine at birth could dampen BCG's broader mortality benefit — a claim that leading vaccinologists call unsupported. Paul Offit of Children's Hospital of Philadelphia called the hypothesis "fanciful," noting the hepatitis B vaccine is a single protein among billions the immune system encounters daily, and that decades of data from hundreds of millions of children show no such effect. The consent structure compounded the ethical failure. Mothers who declined to enroll their children in the trial would receive no vaccine at all, creating what Danish researcher Henrik Støvring described as inherently coercive: a 50% chance of vaccination inside the trial versus 0% outside it. Guinea-Bissau does not plan to offer universal hepatitis B birth-dose vaccination until 2028, meaning the trial exploited a coverage gap it could have helped close. The $3.2 million in funding — split between the CDC ($1.6M) and private partners including Bill Ackman's Pershing Square Foundation and the Bluebell Foundation ($1.6M) — was earmarked for a study rather than a rollout. The WHO recommends all infants receive hepatitis B vaccine within 24 hours of birth. Guinea-Bissau has high rates of chronic hepatitis B, making the birth dose particularly critical. Every dollar spent studying whether to give a proven vaccine is a dollar not spent giving it. Schaltz-Buchholzer's post-cancellation messaging raises further concerns. He cast doubt on the hepatitis B vaccine's effectiveness and safety, mentioned the trial would have examined "neurodevelopmental conditions" as side effects — an implicit nod to long-debunked vaccine-autism claims — and framed the shutdown as resistance to challenging "prevailing medical assumptions." Dozens of studies have shown no link between vaccination and autism. The Guinea-Bissau government now controls the seized vaccines. The immediate question is whether those doses reach newborns. The CDC has not responded to questions about redirecting its $1.6M appropriation toward a universal rollout rather than research. WHO spokesperson Tarik Jašarević reaffirmed the organization's recommendation for timely, evidence-based hepatitis B protection for all newborns worldwide. The episode exposes a recurring pattern in global health: well-funded researchers from wealthy nations designing trials in low-income countries that test hypotheses their home institutions would never approve, exploiting populations whose lack of access to standard care makes them available as subjects. The study didn't create knowledge — it created risk for children who should have been vaccinated.
